INNOVATIVE SOLUTIONS & SUPPORT INC (ISSC): REPORTS THIRD QUARTER FISCAL 2026 RESULTS

INNOVATIVE SOLUTIONS & SUPPORT INC (ISSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVATIVE AEROSYSTEMS REPORTS THIRD QUARTER FISCAL 2026 RESULTS Exton, PA, August 13, 2026 – Innovative Solutions & Support, Inc. (Nasdaq: ISSC) dba Innovative Aerosystems and its subsidiaries (“IA”) or the "Company", a leading provider of advanced avionic solutions

Event · Earnings
Original reporting
Published Aug 13, 2026, 1:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ISSC
Bullish
medium confidence
Mentioned
$ISSC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ISSCBullishMed
01

Why it matters

Traders can update valuation and near-term positioning based on the quantified earnings and cash-flow improvements, backlog level, and liquidity/net-debt metrics, plus corporate actions (ticker change) and strategic progress (Aydin Displays acquisition, eVTOL display/avionics agreement).

02

Market read

Fresh Q3 earnings and cash-flow metrics, plus backlog and liquidity, provide a concrete basis for re-rating ISSC’s near-term fundamentals.

03

What to watch

Backlog is $82.9M and includes exclusions for potential sole-source future orders; also, elevated F-16 revenues in the prior-year comp were affected by manufacturing transition, which may distort normalized comparisons.

Relevance 7/10Novelty 8/10Timing: filed pre-market today (Aug 13, 2026) with Q3 fiscal results and balance-sheet updates

Background

Innovative Solutions & Support, Inc. (dba Innovative Aerosystems) filed an 8-K with Exhibit 99.1 reporting fiscal 2026 third-quarter results and related financial condition updates.

Company-level read

Ticker impact

$ISSCBullishMedium confidence
Context

ISSC reported fiscal 2026 Q3 results, including net sales of $26.7M (+10.7%) and gross margin of 51.7%, plus $12.3M YTD free cash flow.

Expected impact

Likely modest positive bias for the next session as traders digest improved margins, cash generation, and backlog, though magnitude depends on Street expectations.

Evidence & confidence

This is a primary 8-K earnings release with multiple quantified improvements (revenue, margin, adjusted EBITDA, free cash flow) and balance-sheet liquidity (cash $53.7M, net debt/TTM adj EBITDA 1.4x).

Market effects

Signals improving profitability and cash generation in advanced avionics, potentially supporting sentiment toward small-cap defense-adjacent suppliers.

No clear regional read-through beyond Exton facility transition mentioned.

Limited global impact; includes a Japanese eVTOL design agreement and military-related backlog, but no cross-border financial guidance disclosed.

Counterpoint

Despite strong margin and cash-flow growth, operating expenses rose and net debt increased year over year, which could cap upside if financing costs or working-capital needs re-emerge.

Key entities

  • Innovative Solutions & Support, Inc.

    Nasdaq-listed company reporting fiscal 2026 Q3 results and financial condition in an SEC 8-K.

  • Aydin Displays

    Acquisition completed in July 2026, described as complementary display technologies for military and defense markets.

  • Liberty Flight Deck platform

    Management cites the first production award for primary display and avionics architecture tied to an eVTOL program.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.